Insmed Incorporated (BMV:INSM)
Mexico
· Delayed Price · Currency is MXN | Market Cap | 506.60B |
| Revenue (ttm) | 10.92B |
| Net Income (ttm) | -22.99B |
| Shares Out | n/a |
| EPS (ttm) | -115.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 125 |
| Average Volume | 842 |
| Open | 3,760.00 |
| Previous Close | 2,407.92 |
| Day's Range | 3,760.00 - 3,760.00 |
| 52-Week Range | 1,915.00 - 3,760.00 |
| Beta | n/a |
| RSI | n/a |
| Earnings Date | May 7, 2026 |
About Insmed
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ... [Read more]
Financial Performance
In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.
Financial numbers in USDNews
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
BRIDGEWATER, N.J., April 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Insmed discontinues development of skin condition drug after mid-stage study miss
Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.
Insmed Provides Clinical Update on Phase 2b CEDAR Study
—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose...
Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path
The ENCORE study's results indicate that Arikayce (amikacin liposome inhalation suspension), in combination with a multidrug therapy, met its primary and all secondary endpoints, showcasing its potent...
Insmed Transcript: Study result
The ENCORE phase III trial showed ARIKAYCE plus standard therapy significantly improved respiratory symptoms and culture conversion rates in newly diagnosed or recurrent MAC lung infection, with a favorable safety profile and lower discontinuation rates. These results support regulatory submissions for label expansion and could establish ARIKAYCE as a new standard of care.
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
—The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom Sco...
Insmed Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a diversified pipeline with two commercial products, major clinical readouts for ARIKAYCE and brensocatib, and a robust launch strategy targeting significant patient populations. TPIP and early-stage assets offer additional growth, with multiple phase 3 programs underway.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., March 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Insmed Transcript: TD Cowen 46th Annual Health Care Conference
Q4 revenue far exceeded expectations, driven by broad physician adoption and strong patient outcomes. Growth is expected to continue as positive experiences drive deeper prescribing, with future upside from broader patient populations and pipeline catalysts.
Insmed Earnings Call Transcript: Q4 2025
2025 saw a transformative launch for BRINSUPRI, driving strong revenue growth and positioning for at least $1B in 2026, while ARIKAYCE and TPIP also advanced. Cash flow positivity is expected without new capital, and market access for BRINSUPRI remains highly favorable.
Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
—Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE ® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Mil...
Insmed To Present at March 2026 Investor Conferences
BRIDGEWATER, N.J., Feb. 13, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
BRIDGEWATER, N.J., Feb. 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in Pulmona...
Insmed CEO Will Lewis talks its rare disease drug pipeline
Will Lewis, Insmed CEO, joins 'Fast Money' to talk the rare disease pipeline, acquisitions in the pharma space, and more.
Insmed Transcript: 44th Annual J.P. Morgan Healthcare Conference
Management outlined robust growth across three therapeutic areas, highlighted by a strong BRINSUPRI launch, expanding pipeline, and significant upcoming clinical milestones. International launches and business development are set to drive further value.
Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances
Insmed Inc (NASDAQ: INSM) on Friday outlined a commercial and clinical roadmap for 2026, highlighting strong momentum from its respiratory portfolio and a series of upcoming trial readouts and launche...
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
— BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025— —ARIKAYCE® (amikacin liposome in...
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J., Jan. 2, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $INSM--INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm.
Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news
Mizuho's Jared Holz joins 'Fast Money' to talk Insmed shares tanking on discontinuing development of sinus drug.
Why Is Insmed Stock Falling Thursday?
Insmed Incorporated (NASDAQ: INSM) stock plunged on Thursday.
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.
Insmed Stock Plummets 19%. This Is What Sparked the Selloff.
The biopharmaceutical company said it was discontinuing development of a drug treating a chronic sinus condition.
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.